Stock Track | Pliant Therapeutics Shares Plunge Despite Beating Q3 Earnings Estimates

Stock Track

Nov 09, 2024

Shares of Pliant Therapeutics, Inc. (PLRX) plummeted by 5.99% on Wednesday, despite the biopharmaceutical company reporting better-than-expected earnings for the third quarter of 2024.

According to the company's earnings report, Pliant Therapeutics reported an adjusted loss of $0.95 per share for the quarter ended September 30, 2024, beating analysts' consensus estimate of a $0.97 loss per share. However, the company recorded zero revenue for the quarter, falling short of analysts' expectations of around $0.5 million.

Despite the narrower-than-expected loss, Pliant Therapeutics reported a substantial quarterly net loss of $57.76 million, which may have weighed on investor sentiment. Additionally, while the stock had gained 35.5% during the third quarter, it was still down 16.1% year-to-date, raising concerns about the company's overall performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1116380895"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1116380895\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1116380895?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-09 05:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116380895","market":"us","top_or_hot":-1,"title":"Stock Track | Pliant Therapeutics Shares Plunge Despite Beating Q3 Earnings Estimates","media":"Stock Track","content":"<p>Shares of Pliant Therapeutics, Inc. (PLRX) plummeted by 5.99% on Wednesday, despite the biopharmaceutical company reporting better-than-expected earnings for the third quarter of 2024.</p>\n\n<p>According to the company's earnings report, Pliant Therapeutics reported an adjusted loss of $0.95 per share for the quarter ended September 30, 2024, beating analysts' consensus estimate of a $0.97 loss per share. However, the company recorded zero revenue for the quarter, falling short of analysts' expectations of around $0.5 million.</p>\n\n<p>Despite the narrower-than-expected loss, Pliant Therapeutics reported a substantial quarterly net loss of $57.76 million, which may have weighed on investor sentiment. Additionally, while the stock had gained 35.5% during the third quarter, it was still down 16.1% year-to-date, raising concerns about the company's overall performance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Pliant Therapeutics Shares Plunge Despite Beating Q3 Earnings Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Pliant Therapeutics Shares Plunge Despite Beating Q3 Earnings Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-09 05:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Pliant Therapeutics, Inc. (PLRX) plummeted by 5.99% on Wednesday, despite the biopharmaceutical company reporting better-than-expected earnings for the third quarter of 2024.</p>\n\n<p>According to the company's earnings report, Pliant Therapeutics reported an adjusted loss of $0.95 per share for the quarter ended September 30, 2024, beating analysts' consensus estimate of a $0.97 loss per share. However, the company recorded zero revenue for the quarter, falling short of analysts' expectations of around $0.5 million.</p>\n\n<p>Despite the narrower-than-expected loss, Pliant Therapeutics reported a substantial quarterly net loss of $57.76 million, which may have weighed on investor sentiment. Additionally, while the stock had gained 35.5% during the third quarter, it was still down 16.1% year-to-date, raising concerns about the company's overall performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PLRX","symbol_name":"Pliant Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1116380895","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116380895","pubTimestamp":1731100347,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Pliant Therapeutics, Inc.  plummeted by 5.99% on Wednesday, despite the biopharmaceutical company reporting better-than-expected earnings for the third quarter of 2024.According to the company's earnings report, Pliant Therapeutics reported an adjusted loss of $0.95 per share for the quarter ended September 30, 2024, beating analysts' consensus estimate of a $0.97 loss per share. However, the company recorded zero revenue for the quarter, falling short of analysts' expectations of arou","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PLRX":"Pliant Therapeutics, Inc."},"translate_title":"尽管第三季度盈利超出预期，但Pliant Therapeutics股价仍暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLRX":1},"content_text":"Shares of Pliant Therapeutics, Inc. (PLRX) plummeted by 5.99% on Wednesday, despite the biopharmaceutical company reporting better-than-expected earnings for the third quarter of 2024.\nAccording to the company's earnings report, Pliant Therapeutics reported an adjusted loss of $0.95 per share for the quarter ended September 30, 2024, beating analysts' consensus estimate of a $0.97 loss per share. However, the company recorded zero revenue for the quarter, falling short of analysts' expectations of around $0.5 million.\nDespite the narrower-than-expected loss, Pliant Therapeutics reported a substantial quarterly net loss of $57.76 million, which may have weighed on investor sentiment. Additionally, while the stock had gained 35.5% during the third quarter, it was still down 16.1% year-to-date, raising concerns about the company's overall performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}